forecast

Deleting PCSK9 could prevent heart attacks

Rare individuals lacking a normal copy of PCSK9 have vanishingly low heart-attack risk yet are otherwise fine, so active efforts—with clinical trials possibly starting as early as 2022—aim to prospectively delete this gene in people at severe cardiovascular risk before they suffer a heart attack.

forecastpending

Speaker

Fyodor Urnov

Evidence Quote

“We ask gene editors to get rid of it and in fact, there are active efforts and clinical trials could start as early as 2022”

Source

112 | Fyodor Urnov on Gene Editing, CRISPR, and Human Engineering— Sean Carroll's Mindscape
Created: 6/13/2026, 3:37:39 AM

Your notes

Loading notes...